What Phibro Animal Health Corp told the SEC could break it.

Phibro's Brazilian manufacturing facilities accounted for 10% of consolidated assets at June 30, 2025, concentrating part of its production in Brazil's economic/political environment.

“We have manufacturing facilities located in Brazil and a portion of our sales and earnings is attributable to products produced and operations conducted in Brazil. Our Brazilian manufacturing facilities and local operations accounted for 10% and 14% of our consolidated assets, as of June 30, 2025 and 2024”

Phibro's Israeli manufacturing facilities accounted for 16% of consolidated assets at June 30, 2025, exposing it to regional armed conflict (Israel–Hamas and potential broader regional war).

“We have manufacturing facilities located in Israel and a portion of our net sales and earnings is attributable to products produced and operations conducted in Israel. Our Israeli manufacturing facilities and local operations accounted for 16% and 28% of our consolidated assets, as of June 30, 2025 and 2024”

Several core Phibro products (virginiamycin, oxytetracycline, neomycin, streptomycin, tiamulin, chlortetracycline, sulfamethazine) are on the FDA's medically-important-antimicrobial GFI #152 list; FDA review could bring increased use/labeling restrictions, threatening a product line that is ~50% of net sales.

“Our products that contain virginiamycin, oxytetracycline, neomycin, streptomycin, tiamulin, chlortetracycline, or sulfamethazine are classified by the FDA as medically important antimicrobials and are included in the GFI 152 list. The FDA announced its intention to further review the GFI 152 list and to review labeling directions of products on the GFI 152 list, which may lead to increased restrictions on the use of these products.”

Phibro buys APIs from CMOs in China, India and elsewhere and may face new/increased tariffs on imported raw materials with limited ability to pass the costs to customers.

“we may be subject to new or increased tariffs on imported raw materials with limited ability to pass those increased costs through to our customers.”

Phibro's medicated-products business is a relatively small number of compounds yet ~50% of net sales (FY2025); a significant loss of antibacterial sales from bans, restrictions, public perception or competition would be material.

“Our medicated products business is comprised of a relatively small number of compounds and accounted for approximately 50% and 40% of net sales for the years ended June 30, 2025 and 2024, respectively.”

Phibro's Mineral Nutrition business raw-material costs track global commodity markets (e.g. copper and trace minerals), with cost changes flowing directly into its revenues; it generally does not hedge raw-material costs.

“The costs of raw materials used by our Mineral Nutrition business are particularly subject to fluctuations in global commodities markets and cost changes in the underlying commodities markets typically lead directly to a corresponding change in our revenues.”

Phibro receives certain active ingredients/products from sole-source suppliers, and new facilities require regulatory approval — so an interruption could prevent timely product supply to customers.

“While we take measures where economically feasible and available to secure back-up suppliers, the continued receipt of active ingredients or products from a sole source supplier could create challenges if a sole source was interrupted.”